The study by Riemenschneider et al1 suggests that markers of Alzheimer disease (AD) can be detected when patients are in the mild cognitive impairment (MCI) stage and that these markers are associated with the progression of cognitive symptoms. We wish to place the results of their study in a clinical context to imply that the detection of the biological "fingerprint" of AD in patients with MCI might be sufficiently accurate for clinical decisions.
Frisoni GB, Padovani A, Wahlund L. The Diagnosis of Alzheimer Disease Before It Is Alzheimer Dementia. Arch Neurol. 2003;60(7):1023. doi:10.1001/archneur.60.7.1023-a